Discover more insights into Mismatch Repair Deficient 불일치 복구 결함

Keywords frequently search together with Mismatch Repair Deficient 불일치 복구 결함

Narrow sentence examples with built-in keyword filters

Mismatch Repair Deficient sentence examples within microsatellite instability high



Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.


Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.

Mismatch Repair Deficient sentence examples within mismatch repair proficient



Loss of ACKR4 in tumor cells dysregulates dendritic cell migration to tumor-draining lymph nodes and T-cell priming


Spatially organized multicellular immune hubs in human colorectal cancer

Mismatch Repair Deficient sentence examples within immune checkpoint inhibitor



Mismatch Repair (MMR) gene alteration and BRAF V600E mutation are potential predictive biomarkers of immune checkpoint inhibitors in MMR-deficient colorectal cancer.


Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches


Learn more from Mismatch Repair Deficient 불일치 복구 결함


Mismatch Repair Deficient sentence examples within immune checkpoint blockade



Mismatch repair deficiency is implicated in carcinoma arising from ovarian teratoma.


Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.

Mismatch Repair Deficient sentence examples within first line treatment



The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer


Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.

Mismatch Repair Deficient sentence examples within p53 wild type



Molecular Classification to Prognosticate Response in Medically Managed Endometrial Cancers and Endometrial Intraepithelial Neoplasia


Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer

Mismatch Repair Deficient sentence examples within specific molecular profile



TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.


Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.

Mismatch Repair Deficient sentence examples within p53 abnormal p53abn



Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis.


Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.

Mismatch Repair Deficient sentence examples within tumor mutational burden



Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis

Mismatch Repair Deficient sentence examples within Dna Mismatch Repair Deficient



Abstract 4921: TGF-beta signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types


Novel Methods to Overcome Acquired Resistance to Immunotherapy

Mismatch Repair Deficient sentence examples within Develop Mismatch Repair Deficient



Unraveling the heterogeneous mutational signature of spontaneously developing tumors in MLH1-/- mice


The mutational signature of spontaneously developing tumours in MLH1-/- mice: Potential consequences for immunotherapeutic approaches

Mismatch Repair Deficient sentence examples within Risk Mismatch Repair Deficient



3 Translating endometrial molecular risk stratification to endometrioid ovarian carcinoma: a novel application of precision medicine


Application of precision medicine: can molecular risk stratification provide new management options for low stage endometrioid ovarian carcinoma?

Mismatch Repair Deficient sentence examples within mismatch repair deficient tumor



Abstract 2677: MSIClass–Identification and classification of microsatellite unstable using cell-free DNA from ultra-low-pass sequencing


Different responses to anti-programmed cell death protein 1 (PD-1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report

Mismatch Repair Deficient sentence examples within mismatch repair deficient tumour



Mismatch repair deficiency is implicated in carcinoma arising from ovarian teratoma.


The Australian Exceptional Responders Program: A national collaboration


Management of small bowel adenocarcinoma: making the most of the available evidence to inform routine practice



Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough.



Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab



ASO Visual Abstract: ATMIN Suppresses Metastasis by Altering the WNT Signaling Pathway via PARP1 in MSI-High Colorectal Cancer



Poorly Cohesive Carcinoma of the Nonampullary Small Intestine: A Distinct Histologic Subtype With Prognostic Significance.



Single-Cell Analysis Reveals Multicellular Immune Hubs in Colon Cancer.



Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells



Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors



Targeting DNA damage repair pathways in pancreas cancer.



Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse



Complete Genome Sequence of Streptococcus pneumoniae Strain Rx1, a Hex Mismatch Repair-Deficient Standard Transformation Recipient



Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer



A durable response to pembrolizumab in a patient with uterine serous carcinoma and Lynch syndrome due to the MSH6 germline mutation.



Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer



Comprehensive analysis of DNA mismatch repair-deficient gastric cancer in a Japanese hospital-based population.



Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)



PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells



Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.



Pre-therapeutic Evaluation of Patient-Specific Responses to Immune-Checkpoint Inhibition in Colorectal Cancer



Abstract B094: Successful identification of neoantigen-specific T-cell responses in low mutation burden colorectal cancers for personalized cancer vaccine development



Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists



Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer



Inside the USCAP Journals



FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1



Exploring the genetic basis of Lynch-like syndrome through paired germline and tumor exome sequencing.



Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy?



Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.



Identification of Lynch syndrome by microsatellite instability and mismatch repair deficiency testing on colorectal adenomas



P87 Mesenchymal splice isoform fibroblast growth factor receptor (FGFR2c) is an independent prognostic biomarker and further refines risk stratification within endometrial cancer molecular subtypes



Tissue-agnostic cancer drugs in the fight against molecular subsets of metastases of unknown origin



EP563 Mismatch repair deficiency glands in normal endometrial tissue as a predictor of endometrial carcinoma in patients with lynch syndrome



Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1−/− Mice



Lynch‐like syndrome is as frequent as Lynch syndrome in early‐onset nonfamilial nonpolyposis colorectal cancer



PD-1 Blockade in Advanced Adrenocortical Carcinoma.



6 Interpreting immune infiltrates and hormone biomarkers in young women with endometrial carcinoma (EC) through a moder lens (POST-TCGA) of molecular classification


Learn more from Mismatch Repair Deficient 불일치 복구 결함